Gary Marcus questions Anthropic's IPO valuation
AI summary
Gary Marcus argues that Anthropic may not sustain the exponential revenue growth assumed by bullish investors, citing data he says shows revenue growth has leveled off amid stronger competition from Chinese models. He also dismisses promises about medicine as unrealistic and urges prospective investors not to buy Anthropic stock “for the sake of humanity.”
In-depth insight
The article presents a clearly stated bear case against Anthropic’s IPO valuation, while its revenue and competitive claims are not independently substantiated in the supplied report.
This source provides an excerpt. Continue reading on the original site.